Full Press Release Details
Enlivex Strengthens Management Team with the Appointment of Biotech
Industry Veteran Einat Galamidi, M.D., as Vice President, Medical
Nes Ziona, Israel, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Enlivex
Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced
that Einat Galamidi, M.D. has joined its executive management team as Vice President, Medical.
Dr. Galamidi joins Enlivex after 10 years at Gamida Cell, where
she most recently served as Vice President of Clinical Development. At Gamida Cell, she led clinical development for omidubicel, a cell
therapy under development as a potential bone marrow transplant solution for patients with blood cancers. Omidubicel successfully completed
a Phase III program in 2020 and is the subject of a recently initiated rolling Biologics License Application (BLA) submission. Dr. Galamidi
earned her M.D. at the Hadassah School of Medicine at the Hebrew University of Jerusalem.
"Einat is a highly talented industry veteran, and we are
thrilled that she is joining our team," said Oren Hershkovitz, Ph.D., Chief Executive Officer of Enlivex. "At Gamida Cell,
she successfully led the clinical development of omidubicel, a cell therapy designed for cancer patients, for which a Biologics License
Application (BLA) submission was recently initiated. Such experience, specifically in the cell therapy space, makes Einat well suited
for her new role at Enlivex."
Dr. Galamidi added, "The opportunity to join Enlivex's
executive management team is truly exciting. I believe that the Company has generated encouraging clinical data for Allocetra in sepsis
and COVID-19 patients, as well as meaningful preclinical data in solid tumors. I am eager to begin working with my new colleagues and
believe that our complementary skill sets will serve us well as we continue to advance Allocetra's development."
AllocetraTM is being developed as a universal,
off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis,
COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly
to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide
a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet medical
needs", as a stand-alone therapy or in combination with leading therapeutic agents.
Enlivex is a clinical stage immunotherapy company developing AllocetraTM,
a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic
macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For
more information, visit http://www.enlivex.com.
Safe Harbor Statement: This press release contains forward-looking
statements, which may be identified by words such as "expects," "plans," "projects," "will,"
"may," "anticipates," "believes," "should," "would", "could,"
"intends," "estimates," "suggests," "has the potential to" and other words of similar
meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical
experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements
are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned
that forward-looking statements involve risks and uncertainties that may affect Enlivex's business and prospects, including
the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in
development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval
or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show
substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the
forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of
clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage
trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other
factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making,
the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary
rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the
economic, competitive, governmental, technological and other factors discussed in Enlivex's filings with the
Securities and Exchange Commission, including in the Company's most recent Annual Report on Form 20-F filed with the Securities
and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements
were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
INVESTOR RELATIONS CONTACT